Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WH008
- Development stage
- Preclinical
- Lead developer
- Beijing Wehand-Bio Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
WH008 is a small molecule drug candidate, characterized as a natural medicine, being developed by Beijing Wehand-Bio Pharmaceutical. It is currently in development for the treatment of Metabolic-Associated Steatohepatitis (MASH), formerly known as Non-alcoholic Steatohepatitis (NASH). As a natural medicine, it is likely derived from or based on a natural product, which is a primary focus of the sponsor's pipeline. The specific molecular target and mechanism of action for WH008 have not been publicly disclosed, but the compound is intended to address the metabolic dysfunction and liver inflammation associated with MASH.
Beyond the preview
Go deeper on WH008.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WH008.